Theravance Share Price

Theravance Share Price

NASDAQ: TBPH | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Theravance Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Theravance Share Price Chart

$0.00$0.00
L
Show Current Price
H

Theravance Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
16.43
Dividend Yield
0.00%
EPS (TTM)
$1.04
Revenue (TTM)
$107.46B
Return On Equity (TTM)
18.57%
Profit Margin
98.55%
Debt to Equity
0.01
Quarterly Earnings Growth YoY
-262.98%

Theravance Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$19.99$45.89$17.70$20.73
Net Profit$3.62$61.02-$4.93-$5.90
Net Profit Margin18.11%132.97%-27.85%-28.46%
Income ChangeN/A1585.64%-108.08%-19.68%

Theravance Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$51.35$57.42$64.38$107.46
Net Profit$872.13-$55.19-$56.42$105.90
Net Profit Margin1698.40%-96.12%-87.64%98.55%
Income ChangeN/A-106.33%-2.23%287.70%

Theravance Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets67.11193.09248.46253.94
Current Assets418.46161.07133.54353.46
Total Assets485.57354.16382.0607.4
Non Current Liabilities117.75116.2144.24136.89
Current Liabilities71.162.4224.7728.72
Total Liabilities188.85178.62169.0165.6
Shareholders' Equity296.72175.55213.0441.8

Theravance Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating238.54-11.54-27.0-186.99
Investing-105.2812.28-32.71,154.01
Financing-3.25-2.5-198.93-758.81

About Theravance

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Theravance Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

Theravance Share Price FAQs